Source: Virtual Congress 2020 – Diagnosis and management of COPD
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
T. Hering (Berlin, Germany), N. Kossack (Leipzig, Germany), A. Krinner (Leipzig, Germany), D. Bulenda (Heidenheim, Germany). Valdation study of MEP-questionnaire for detection of exacerbations (Ebs) - interim analysis. 114

Member's Comments

No comment yet.

Related content which might interest you: Indacaterol/glycopyrronium (IND/GLY) is more effective than salmeterol/fluticasone (SFC) in reducing exacerbations, regardless of outcome measurement utilised: Results from the FLAME study Source: International Congress 2016 – Novel insights into the treatment of COPD Year: 2016 Direct cost analysis of COPD patients: A 1 year follow-up study Source: International Congress 2016 – Novel avenues in the treatment of COPD II Year: 2016 Pooled analyses of five phase 2b studies support dose selection of glycopyrrolate-formoterol (GFF) MDI (PT003) 18/9.6 μg for phase III development Source: Annual Congress 2013 –COPD drugs: new findings Year: 2013 The Spanish national clinical audit on COPD exacerbations (eCOPD). Pilot study: selection of study subjects Source: Annual Congress 2008 - COPD in the elderly - quality of life and scores in COPD Year: 2008 Indacaterol/glycopyrronium (IND/GLY) reduces the risk of clinically important deterioration (CID) versus open-label tiotropium (Tio) in COPD patients: Post hoc analysis from SHINE and SPARK studies Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 Four years follow-up of exacerbations in a cohort of COPD patients: 1 year interim results (EXACO study) Source: Annual Congress 2008 - COPD - clinical and epidemiological aspects Year: 2008 Indacaterol/glycopyrronium (IND/GLY) delays clinically important deterioration (CID) versus salmeterol/fluticasone (SFC) in symptomatic COPD patients: LANTERN/ILLUMINATE pooled analysis Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 Latent class analyses used to study phenotypes in severe COPD with exacerbation. A pilot study Source: Annual Congress 2010 - Epidemiological data for smoking control Year: 2010 The effect of outpatient pulmonary rehabilitation on COPD assessment test (CAT) and GOLD classification – A retrospective data analysis Source: International Congress 2015 – Latest insights into pulmonary rehabilitation Year: 2015 COPD severity analysis according to current evaluation criteria – National survey Source: International Congress 2015 – Clinical assessment and monitoring of asthma and COPD Year: 2015 Is treatment with ICS and LABA cost-effective for COPD? Multinational economic analysis of the TORCH study Source: Eur Respir J 2010; 35: 532-539 Year: 2010 Statistical analysis of anthropometric differences between COPD stages 1 and 2 Source: International Congress 2016 – Features and impact of comorbidities in COPD Year: 2016 Exacerbations in a cohort of COPD patients: frequent exacerbators characteristics after 1-year follow-up (EXACO study – interim analysis) Source: Annual Congress 2008 - COPD - clinical and epidemiological aspects Year: 2008 Colonisation in stable patients with COPD: results of an Italian epidemiological study (PRIME study) Source: Annual Congress 2005 - Acute and chronic infections in COPD Year: 2005 Indacaterol/glycopyrronium (IND/GLY) reduces exacerbations compared with salmeterol/fluticasone (SFC) in various sub-groups from the FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 The long-term clinical and economic impact of COPD exacerbations: an observational study (SHERLOCK) Source: Virtual Congress 2020 – Prediction and management of outcomes in obstructive diseases Year: 2020 Indacaterol/glycopyrronium (IND/GLY) reduces exacerbation and improves lung function versus salmeterol/fluticasone (SFC) in patients with and without prior ICS use: The FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 Analysis of the frequency of COPD exacerbations in the ’real-life’ DACCORD study over a 2 year period Source: International Congress 2016 – Comorbidities and exacerbations in COPD Year: 2016 A new treatment algorithm for acute exacerbation of IPF: a retrospective cohort study. Source: International Congress 2019 – Recent developments in intensive care unit medicine Year: 2019 Pooled analyses of QTcF across six phase 2b studies with glycopyrrolate-formoterol fumarate (GFF) MDI (PT003), its components and active comparators Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD Year: 2013